| Document Date: 2014-06-16 21:54:26
Open Document File Size: 135,14 KBShare Result on Facebook
City New York / Meriden / / Company Protein Sciences Corporation / Protein Sciences Corporation For Immediate Release June / FFF Enterprises / / Currency USD / / Event Business Partnership / M&A / FDA Phase / / IndustryTerm Healthcare professionals / egg-free system using modern cell culture technology / manufacturing / recombinant technology / larger-scale manufacturing facility / pandemic solution / healthcare professional / prevention of seasonal influenza disease / / MedicalCondition severe allergic reaction / influenza disease / infectious influenza virus / headache / recombinant influenza / anaphylaxis / pain / severe muscle weakness / fatigue / muscle aches / seasonal influenza disease / ever experienced Guillain-Barré syndrome / influenza / conventional influenza / only flu / / MedicalTreatment antibiotics / vaccination / / Organization U.S. Department of Health and Human Services / FDA / U.S. Biomedical Advanced Research and Development Authority / / Person Manon Cox / / / Position President and CEO / President & CEO / / Product Panblok® (pandemic) / Panblok / Flublok / / ProvinceOrState New York / / PublishedMedium PLOS ONE / / Technology biopharmaceuticals / cell culture technology / recombinant technology / / URL www.Flublok.com / www.proteinsciences.com / /
SocialTag |
U.S. Biomedical Advanced Research and Development Authority (BARDA) Extends Contract with Protein Sciences Corporation For Immediate Release June 17, 2014